Cerus (CERS) 10-Q1 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2013	Oct. 28, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CERS	'
Entity Registrant Name	'CERUS CORP	'
Entity Central Index Key	'0001020214	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	70,456,000

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$24,355	$26,696
Investments	28,971	'
Accounts receivable	7,025	4,444
Inventories	12,686	10,180
Prepaid expenses	1,071	638
Other current assets	394	2,038
Total current assets	74,502	43,996
Non-current assets:	'	'
Property and equipment, net	1,848	1,698
Goodwill	1,316	1,316
Intangible assets, net	1,395	1,546
Restricted cash	306	304
Other assets	72	59
Total assets	79,439	48,919
Current liabilities:	'	'
Accounts payable	4,076	7,186
Accrued liabilities	12,060	7,619
Deferred revenue	111	77
Debt - current	3,638	4,828
Warrant liability	22,706	5,903
Total current liabilities	42,591	25,613
Non-current liabilities:	'	'
Debt - non-current	'	2,896
Deferred income taxes	82	62
Other non-current liabilities	1,120	1,241
Total liabilities	43,793	29,812
Commitments and contingencies	'	'
Common stock	70	56
Additional paid-in capital	532,938	478,903
Accumulated other comprehensive loss	-33	'
Accumulated deficit	-497,329	-459,852
Total stockholders' equity	35,646	19,107
Total liabilities and stockholders' equity	$79,439	$48,919

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue:	'	'	'	'
Product revenue	$10,542	$8,252	$30,425	$26,167
Cost of product revenue	6,826	4,411	17,663	15,499
Gross profit on product revenue	3,716	3,841	12,762	10,668
Government grants and cooperative agreements revenue	'	'	'	91
Operating expenses:	'	'	'	'
Research and development	4,363	1,903	10,569	5,439
Selling, general and administrative	7,728	6,219	22,535	18,871
Amortization of intangible assets	50	50	151	151
Total operating expenses	12,141	8,172	33,255	24,461
Loss from operations	-8,425	-4,331	-20,493	-13,702
Non-operating income (expense), net:	'	'	'	'
Revaluation of warrant liability	-12,416	873	-16,803	86
Foreign exchange gain (loss)	409	187	198	-53
Interest expense	-41	-136	-279	-410
Other income, net	32	2	65	9
Total non-operating income (expense), net	-12,016	926	-16,819	-368
Loss before income taxes	-20,441	-3,405	-37,312	-14,070
Provision for income taxes	60	55	165	131
Net loss	($20,501)	($3,460)	($37,477)	($14,201)
Net loss per common share:	'	'	'	'
Basic	($0.29)	($0.06)	($0.56)	($0.26)
Diluted	($0.29)	($0.08)	($0.56)	($0.26)
Weighted average common shares outstanding used for calculating net loss per common share:	'	'	'	'
Basic	69,791	54,875	66,464	54,130
Diluted	69,791	55,377	66,464	54,130

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	($20,501)	($3,460)	($37,477)	($14,201)
Other comprehensive loss:	'	'	'	'
Net unrealized losses on available-for-sale securities, net of taxes	-33	'	-33	'
Comprehensive loss	($20,534)	($3,460)	($37,510)	($14,201)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating activities	'	'
Net loss	($37,477)	($14,201)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	410	582
Stock-based compensation	2,415	1,911
Changes in revaluation of warrant liability	16,803	-86
Deferred income taxes	20	'
Non-cash interest expense	'	15
(Gain)/Loss on disposal of equipment	96	-9
Changes in operating assets and liabilities:	'	'
Accounts receivable	-2,581	2,146
Inventories	-1,345	-3,238
Other assets	154	-2,006
Accounts payable	-3,110	1,020
Accrued liabilities	4,448	2,219
Deferred revenue	34	605
Net cash used in operating activities	-20,133	-11,042
Investing activities	'	'
Purchases of furniture, equipment and leasehold improvements	-440	-97
(Purchases) sales of certain other assets	-14	1
(Purchases) Maturities of investments	-29,162	287
Net cash provided by (used in) investing activities	-29,616	191
Financing activities	'	'
Net proceeds from equity incentives	595	281
Net proceeds from public offering	50,981	10,823
Proceeds from warrant exercises	'	17
Proceeds from revolving line of credit	2,008	1,219
Payments on debt and landlord provided leasehold incentives	-6,176	-325
Net cash provided by financing activities	47,408	12,015
Net increase in cash and cash equivalents	-2,341	1,164
Cash and cash equivalents, beginning of period	26,696	25,497
Cash and cash equivalents, end of period	24,355	26,661
Supplemental disclosures:	'	'
Cash paid for interest	242	330
Non-cash conversion of preferred stock to common stock	'	9,496
Non-cash settlement of warranty claim	$1,272	'

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2013
Summary of Significant Accounting Policies	'
	Note 1. Summary of Significant Accounting Policies
	Principles of Consolidation and Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (collectively referred to hereinafter as “Cerus” or the “Company”) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of only normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three and nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ending December 31, 2013, or for any future periods.
	These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2012, which were included in the Company’s 2012 Annual Report on Form 10-K, filed with the SEC on March 12, 2013. The accompanying balance sheet as of December 31, 2012, has been derived from the Company’s audited financial statements as of that date.
	Use of Estimates
	The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, which are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.
	Revenue
	The Company recognizes revenue in accordance with ASC Topic 605-25, “Revenue Recognition—Arrangements with Multiple Deliverables,” as applicable. Revenue is recognized when (i) persuasive evidence of an agreement with the funding party exists; (ii) services have been rendered or product has been delivered; (iii) pricing is fixed or determinable; and (iv) collection is reasonably assured. The Company’s main sources of revenues for the three and nine months ended September 30, 2013, and 2012, were product revenue from sales of the INTERCEPT Blood System for platelets and plasma (“platelet and plasma systems”) and United States government grants and awards.
	Revenue related to product sales is generally recognized when the Company fulfills its obligations for each element of an agreement. For all sales of the Company’s INTERCEPT Blood System products, the Company uses a binding purchase order and signed sales contract as evidence of a written agreement. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. Generally, the Company’s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. Deliverables and the units of accounting vary according to the provisions of each purchase order or sales contract. For revenue arrangements with multiple elements, the Company determines whether the delivered elements meet the criteria as separate units of accounting. Such criteria require that the deliverable have stand-alone value to the customer and that if a general right of return exists relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Once the Company determines if the deliverable meets the criteria for a separate unit of accounting, the Company must determine how the consideration should be allocated between the deliverables and how the separate units of accounting should be recognized as revenue. Consideration received is allocated to elements that are identified as discrete units of accounting based on the best estimated selling price. The Company has determined that vendor specific objective evidence is not discernible due to the Company’s limited history of selling its products and variability in its pricing across the regions into which it sells its products. Since the Company’s products are novel and unique and are not sold by others, third-party evidence of selling price is unavailable.
	At both September 30, 2013, and December 31, 2012, the Company had $0.1 million of short-term deferred revenue on its condensed consolidated balance sheets related to future performance obligations. Freight costs charged to customers are recorded as a component of revenue under ASC Topic 605, “Accounting for Shipping and Handling Fees and Costs.” Value-added-taxes (“VAT”) that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such VAT from product revenue.

	Revenue related to the cost reimbursement provisions under development contracts or United States government grants is recognized as the costs on the projects are incurred. The Company has received certain United States government grants and contracts that support research in defined research projects. These grants generally have provided for reimbursement of approved costs incurred as defined in the various grants.
	Research and Development Expenses
	In accordance with ASC Topic 730, “Accounting for Research and Development Expenses,” research and development expenses are charged to expense when incurred, including cost incurred under each grant that has been awarded to the Company by the United States government or development contracts. Research and development expenses include salaries and related expenses for scientific personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of research and development facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.
	The Company’s use of estimates in recording accrued liabilities for research and development activities (see “Use of Estimates” above) affects the amounts of research and development expenses recorded and revenue recorded from development funding and government grants and collaborative agreements. Actual results may differ from those estimates under different assumptions or conditions.
	Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.
	Short-Term Investments
	Investments with original maturities of greater than three months but less than one year from the date of purchase as well as available-for-sale investments with original maturities of greater than one year from the date of purchase, which included corporate bonds and United States government agency securities, are classified as short-term investments. In accordance with ASC Topic 320, “Accounting for Certain Investments in Debt and Equity Securities,” the Company has classified all debt securities as available-for-sale at the time of purchase and reevaluates such designation as of each balance sheet date. Available-for-sale securities are carried at estimated fair value. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities are recorded in “Accumulated other comprehensive income” on the Company’s condensed consolidated balance sheets and in “Net unrealized losses on available-for-sale securities, net of taxes” on the Company’s condensed consolidated statements of comprehensive loss. Realized gains and losses from the sale or maturity of available-for-sale investments are recorded in “Other income, net” on the Company’s condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method. The Company reports the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest expense.
	The Company also reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value. Other-than-temporary declines in market value are recorded in “Other income (expense), net” on the Company’s condensed consolidated statements of operations.
	Restricted Cash
	The Company holds a certificate of deposit with a domestic bank for any potential decommissioning resulting from the Company’s possession of radioactive material. The certificate of deposit is held to satisfy the financial surety requirements of the California Department of Health Services and is recorded in “Restricted cash” on the Company’s condensed consolidated balance sheets.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.
	Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and short-term investments are maintained at two major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At September 30, 2013, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents.

	Concentrations of credit risk with respect to trade receivables exist. However, in connection with the Company’s revolving line of credit, as discussed in Note 8 in the Notes to Condensed Consolidated Financial Statements, the Company purchased a credit insurance policy that mitigates some of its credit risk, as the policy will pay either the Company or its lender on eligible claims filed on its outstanding receivables. On a regular basis, including at the time of sale, the Company performs credit evaluations of its customers. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company reserves against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations. The Company has not historically experienced significant bad debt and accordingly has not maintained an allowance for doubtful accounts.
	The Company had three customers that accounted for more than 10% of the Company’s outstanding trade receivables at both September 30, 2013, and December 31, 2012. These customers cumulatively represented approximately 55% and 59% of the Company’s outstanding trade receivables, at September 30, 2013 and December 31, 2012, respectively. To date, the Company has not experienced collection difficulties from these customers.
	Inventories
	At September 30, 2013, and December 31, 2012, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, UVA illumination devices (“illuminators”), and certain replacement parts for the illuminators. Platelet and plasma systems’ disposable kits generally have a two-year life from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time, which can exceed one year, before being incorporated and assembled by Fresenius Kabi AG (“Fresenius”) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be consumed for production of finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company’s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its finished units to meet the Company’s current demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding one year. At September 30, 2013 and December 31, 2012, the Company classified its work-in-process inventory as a current asset on its condensed consolidated balance sheets based on its evaluation that the work-in-process inventory would be consumed for production and subsequently sold within each respective subsequent twelve-month period.
	Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or market value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. Generally, the Company writes-down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in “Cost of product revenue” on the Company’s condensed consolidated statements of operations.
	Property and Equipment, net
	Property and equipment is comprised of furniture, equipment, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements.
	Goodwill and Intangible Assets, net
	Additions to goodwill and intangible assets, net are derived at the time of a business acquisition, in which the Company assigns the total consideration transferred to the acquired assets based on each asset’s fair value and any residual amount becomes goodwill, an indefinite life intangible asset. Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratably amortized over the estimated useful life of ten years. The amortization of the Company’s intangible assets, net, is recorded in “Amortization of intangible assets” on the Company’s condensed consolidated statements of operations.
	Goodwill is not amortized but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. The Company evaluates goodwill on an annual basis on August 31 of each fiscal year. The test for goodwill impairment is a two-step process. The first step compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired and, therefore, the second step of the impairment test is unnecessary. The second step, which is used to measure the amount of impairment loss, compares the implied fair value of each reporting unit’s goodwill with the respective carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess.
	See Note 5 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s impairment analysis and the valuation of goodwill and intangible assets, net.
	Long-lived Assets
	The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets. The Company did not recognize impairment charges related to its long-lived assets during the three and nine months ended September 30, 2013, and 2012.
	Foreign Currency Remeasurement
	The functional currency of the Company’s foreign subsidiary is the United States dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in United States dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in United States dollars using historical exchange rates. Revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company’s condensed consolidated statements of operations. The Company recorded foreign currency gains (losses) of $0.4 million and $0.2 million during the three months ended September 30, 2013, and 2012, respectively, and $0.2 million and $(0.05) during the nine months ended September 30, 2013, and 2012, respectively.
	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with ASC Topic 718, “Compensation—Stock Compensation.” Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.
	For stock-based awards issued to non-employees, the Company follows ASC Topic 505-50, “Equity Based Payment to Non-Employees” and considers the measurement date at which the fair value of the stock-based award is measured to be the earlier of (i) the date at which a commitment for performance by the grantee to earn the equity instrument is reached or (ii) the date at which the grantee performance is complete. The Company recognizes stock-based compensation expense for the fair value of the vested portion of the non-employee stock-based awards in its condensed consolidated statements of operations.
	See Note 11 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s stock-based compensation assumptions and expenses.
	Warrant Liability
	In August 2009, and November 2010, the Company issued warrants to purchase an aggregate of 2.4 million and 3.7 million shares of common stock, respectively. The material terms of the warrants were identical under each issuance except for the exercise price, date issued and expiration date. The Company classified the warrants as a liability on its condensed consolidated balance sheets as the warrants contain certain material terms which require the Company (or its successor) to purchase the warrants for cash in an amount equal to the value of the unexercised portion of the warrants (as determined in accordance with the Black-Scholes option pricing model) in connection with certain change of control transactions. In addition, the Company may also be required to pay cash to a warrant holder under certain circumstances if the Company is unable to timely deliver the shares acquired upon warrant exercise to such holder.
	The fair value of these outstanding warrants is calculated using the binomial-lattice option-pricing model and is adjusted accordingly at each reporting period. The binomial-lattice option-pricing model requires that the Company uses significant assumptions and judgment to determine appropriate inputs to the model. Some of the assumptions that the Company relies on include the probability of a change of control occurring, the volatility of the Company’s stock over the life of the warrant and assumptions and inputs used to value the warrants under the Black-Scholes model should a change of control occur.

	Changes resulting from the revaluation of warrants to fair value are recorded in “Revaluation of warrant liability” on the condensed consolidated statements of operations. Upon the exercise or modification to remove the provisions which require the warrants to be treated as a liability, the fair value of the warrants will be reclassified from a liability to stockholders’ equity on the Company’s condensed consolidated balance sheets and no further adjustment to the fair value would be made in subsequent periods.
	See Note 10 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s valuation of warrant liability.
	Income Taxes
	The Company accounts for income taxes using an asset and liability approach in accordance with ASC Topic 740 “Accounting for Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. ASC Topic 740 requires derecognition of tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance as described in ASC Topic 740 is not an appropriate substitute for the derecognition of a tax position. The Company did not have any recorded liabilities for unrecognized tax benefits at September 30, 2013 or December 31, 2012. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has its accrued for or made payments for interest and penalties. The Company continues to carry a full valuation allowance on all of its deferred tax assets. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company’s tax years 1998 through 2012 remain subject to examination by the taxing jurisdictions.
	Net Loss Per Common Share
	Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per common share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights, warrants and restricted stock units, which are calculated using the treasury stock method, and convertible preferred stock, which is calculated using the if-converted method. Diluted loss per common share also gives effect to potential adjustments to the numerator for changes resulting from the revaluation of warrants to fair value for the period, even if the Company is in a net loss position if the effect would result in more dilution.
	Diluted loss per common share used the same weighted average number of common shares outstanding for the three months ended September 30, 2013 and the nine months ended September 30, 2013, and 2012, as calculated for the basic loss per common share as the inclusion of any potential dilutive securities would be anti-dilutive. In addition, certain potential dilutive securities were excluded from the dilution calculation for the three months ended September 30, 2012, as their inclusion would have been anti-dilutive.
	The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2013, and 2012 (in thousands, except per share amounts):


			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Numerator:
Net loss used for basic calculation		$	(20,501	)	$	(3,460	)	$	(37,477	)	$	(14,201	)
Effect of revaluation of warrant liability			—			(873	)		—			—

Adjusted net loss used for diluted calculation		$	(20,501	)	$	(4,333	)	$	(37,477	)	$	(14,201	)

Denominator:
Basic weighted average number of common shares outstanding			69,791			54,875			66,464			54,130
Effect of dilutive potential common shares resulting from warrants			—			502			—			—

Diluted weighted average number of common shares outstanding			69,791			55,377			66,464			54,130

Net loss per common share:
Basic		$	(0.29	)	$	(0.06	)	$	(0.56	)	$	(0.26	)
Diluted		$	(0.29	)	$	(0.08	)	$	(0.56	)	$	(0.26	)

The table below presents common shares underlying stock options, convertible preferred stock, employee stock purchase plan rights, warrants and restricted stock units that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the three and nine months ended September 30, 2013, and 2012 (shares in thousands):


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
Anti-dilutive common shares			16,651			8,704			16,301			14,813
Guarantee and Indemnification Arrangements
The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company after December 31, 2002. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.
The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. During the year ended December 31, 2012, the Company provided for warranty obligations related to replacement costs for certain of its products that the Company identified were defective or had the potential of being defective. In connection with the warranty obligations provided for in relation to certain of its products during the year ended December 31, 2012, the Company filed a warranty claim against Fresenius, which Fresenius accepted. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheet as of December 31, 2012 representing the full amount of the warranty claim against Fresenius as Fresenius was obliged to supply the Company with replacement products or credit notes for those defective or potentially defective products. The Company also wrote-down the value of certain unsalable inventory of $1.7 million related to these products as an offsetting warranty claim against Fresenius as of December 31, 2012. As of September 30, 2013, the Company no longer has a warranty claim against Fresenius and all unsalable inventory related to this incident has been returned to Fresenius. During the three months ended March 31, 2013, the Company identified a separate production defect related to unsold inventory. The Company’s third party manufacturer has taken responsibility for the cost of replacing such damaged goods, therefore, the Company has borne no costs associated with these defects. Prior to these incidents, there have been very few warranty costs incurred. As a result, the Company did not accrue for any potential future warranty costs at September 30, 2013. In addition, the Company believes that the defective products and those that had the potential of being defective identified during the three months ended March 31, 2013 and during the year ended December 31, 2012 are isolated.
Fair Value of Financial Instruments
The Company determines the fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities and warrant liability. The Company classifies financial instruments within Level 1 if quote prices are available in active markets, which include its money market funds as the money market funds are actively traded in markets and their market price can be readily determined. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company’s available-for-sale securities related to United States government agencies. The available-for-sale securities are held by a custodian who obtains investment prices from a third party pricing provider that uses standard inputs to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable, which include its warrant liability. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.
See Note 2 and 10 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s valuation on financial instruments.

New Accounting Pronouncements
In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income, was amended to require additional information about amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning January 1, 2013, and will provide the additional information when such reclassifications occur. The amendment did not have a material effect on our consolidated financial statements.

Fair_Value_on_Financial_Instru

Fair Value on Financial Instruments	9 Months Ended
Fair Value on Financial Instruments	Sep. 30, 2013
Fair Value on Financial Instruments	'
	Note 2. Fair Value on Financial Instruments

	We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

		•		Level 1: Quoted prices in active markets for identical instruments

		•		Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)

		•		Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)
	To estimate the fair value of Level 2 debt securities as of September 30, 2013 our primary pricing service relies on inputs from multiple industry-recognized pricing sources to determine the price for each investment. Corporate debt and United States government agency securities are systematically priced by this service as of the close of business each business day. If the primary pricing services does not price a specific asset a secondary pricing services are utilized.
	The fair values of certain of the Company’s financial assets and liabilities were determined using the following inputs at September 30, 2013 (in thousands):


			Total		Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active		Observable		Inputs
					Markets for		Inputs		(Level 3)
					Identical		(Level 2)
					Assets
					(Level 1)
	Money market funds (1)		$	7,862	$	7,862	$	—	$	—
	Corporate debt securities (2)			24,948		—		24,948		—
	United States government agency securities (2)			4,023		—		4,023		—

	Total financial assets		$	36,833	$	7,862	$	28,971	$	—


	Warrant liability		$	22,706	$	—	$	—	$	22,706

	Total financial liabilities		$	22,706	$	—	$	—	$	22,706


	-1	Included in cash and cash equivalents on the Company’s condensed consolidated balance sheets.
	-2	Included in short-term investments on the Company’s condensed consolidated balance sheets.
	The fair values of certain of the Company’s financial assets and liabilities were determined using the following inputs at December 31, 2012 (in thousands):


			Total		Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active		Observable		Inputs
					Markets for		Inputs		(Level 3)
					Identical		(Level 2)
					Assets
					(Level 1)
	Money market funds (1)		$	10,268	$	10,268	$	—	$	—

	Total financial assets		$	10,268	$	10,268	$	—	$	—


	Warrant liability		$	5,903	$	—	$	—	$	5,903

	Total financial liabilities		$	5,903	$	—	$	—	$	5,903


	-1	Included in cash and cash equivalents on the Company’s condensed consolidated balance sheets.
	A reconciliation of the beginning and ending balances for warrant liability using significant unobservable inputs (Level 3) from December 31, 2012, to September 30, 2013, was as follows (in thousands):


	Balance at December 31, 2012		$	5,903
	Increase in fair value of warrants			16,803
	Settlement of warrants exercised			—

	Balance at September 30, 2013		$	22,706


See Note 1 and 10 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s valuation techniques and unobservable inputs for warrant liability using significant unobservable inputs (Level 3).
The Company did not have any transfers among fair value measurement levels during the nine months ended September 30, 2013.

Availableforsale_Securities

Available-for-sale Securities	9 Months Ended
Available-for-sale Securities	Sep. 30, 2013
Available-for-sale Securities	'
	Note 3. Available-for-sale Securities
	The following is a summary of available-for-sale securities at September 30, 2013 (in thousands):


		September 30, 2013
		Amortized Cost		Gross			Fair Value
		Amortized Cost		Unrealized Loss			Fair Value
	Money market funds	$	7,862				$	7,862
	United States government agency securities		4,027		(4	)		4,023
	Corporate debt securities		24,977		(29	)		24,948

	Total available-for-sale securities	$	36,866	$	(33	)	$	36,833

	The fair value of the Company’s available-for-sales securities equaled cost at December 31, 2012.
	Available-for-sale securities at September 30, 2013 and December 31, 2012, consisted of the following by original contractual maturity (in thousands):


		September 30, 2013					December 31, 2012
		Amortized Cost		Fair Value			Amortized Cost		Fair Value
	Due in one year or less	$	24,509	$	24,492		$	10,268	$	10,268
	Due greater than one year and less than five years		12,357		12,341			—		—

	Total available-for-sale securities	$	36,866	$	36,833		$	10,268	$	10,268

	The maturities of certain short-term investments were estimated primarily based upon assumed prepayment features and credit enhancement characteristics.
	Gross realized gains from the sale or maturity of available-for-sale investments were zero during each of the three and nine month periods ended September 30, 2013 and 2012. The Company did not record losses on investments experiencing an other-than-temporary decline in fair value nor did it record any gross realized losses from the sale or maturity of available-for-sale investments during the three and nine months ended September 30, 2013, and 2012.

Inventories

Inventories	9 Months Ended
Inventories	Sep. 30, 2013
Inventories	'
	Note 4. Inventories
	Inventories at September 30, 2013 and December 31, 2012, consisted of the following (in thousands):


		September 30,		December 31,
		2013		2012
	Work-in-process	$	4,810	$	3,551
	Finished goods		7,876		6,629

	Total inventories	$	12,686	$	10,180

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, net	9 Months Ended
Goodwill and Intangible Assets, net	Sep. 30, 2013
Goodwill and Intangible Assets, net	'
	Note 5. Goodwill and Intangible Assets, net
	Goodwill
	During the three and nine months ended September 30, 2013, the Company did not dispose of, impair, or recognize additional goodwill. Accordingly, at both September 30, 2013, and December 31, 2012, the carrying amount of goodwill was $1.3 million. The Company performed its annual review of goodwill on August 31, 2013, and noted no indicators of impairment as of that date.
	Intangible Assets, net
	The following is a summary of intangible assets, net at September 30, 2013 (in thousands):


		September 30, 2013
		Gross		Accumulated			Net
		Carrying		Amortization			Carrying
		Amount					Amount
	Acquisition-related intangible assets:
	Reacquired license - INTERCEPT Asia	$	2,017	$	(622	)	$	1,395

	Total intangible assets	$	2,017	$	(622	)	$	1,395

	The following is a summary of intangible assets, net at December 31, 2012 (in thousands):


		December 31, 2012
		Gross		Accumulated			Net
		Carrying		Amortization			Carrying
		Amount					Amount
	Acquisition-related intangible assets:
	Reacquired license - INTERCEPT Asia	$	2,017	$	(471	)	$	1,546

	Total intangible assets	$	2,017	$	(471	)	$	1,546

	The Company recognized $0.05 million in amortization expense related to intangible assets for each of the three months ended September 30, 2013, and 2012, and $0.15 million for each of the nine months ended September 30, 2013, and 2012. During the three and nine months ended September 30, 2013, and 2012, there were no impairment charges recognized related to the acquired intangible assets.
	At September 30, 2013, the expected annual amortization expense of the intangible assets, net is $0.05 million for the remaining three months of 2013, $0.2 million each subsequent year thereafter beginning with the year ending December 31, 2014, through the year ending December 31, 2019, and $0.1 million for the year ending December 31, 2020.

LongTerm_Investments

Long-Term Investments	9 Months Ended
Long-Term Investments	Sep. 30, 2013
Long-Term Investments	'
	Note 6. Long-Term Investments
	In connection with the agreements to license the immunotherapy technologies to Aduro BioTech (“Aduro”) in 2009, the Company received preferred shares of Aduro. Pursuant to these license agreements, the Company is eligible to receive a 1% royalty fee on any future sales resulting from the licensed technology. As of September 2013, the Company’s ownership in Aduro was less than 3% on a fully diluted basis. The carrying value of the Company’s investment in Aduro is zero in its condensed consolidated balance sheets as of December 31, 2012 and September 30, 2013. As of September 30, 2013 the Company has not received any royalties under this agreement.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
Accrued Liabilities	Sep. 30, 2013
Accrued Liabilities	'
	Note 7. Accrued Liabilities
	Accrued liabilities at September 30, 2013 and December 31, 2012, consisted of the following (in thousands):


		September 30,		December 31,
		2013		2012
	Accrued compensation and related costs	$	2,588	$	2,692
	Accrued inventory costs		5,115		2,352
	Accrued contract and other accrued expenses		4,357		2,575

	Total accrued liabilities	$	12,060	$	7,619

Debt

Debt	9 Months Ended
Debt	Sep. 30, 2013
Debt	'
	Note 8. Debt
	Debt at September 30, 2013, consisted of the following (in thousands):


			September 30, 2013
			Principal			Unamortized			Total
			Principal			Discount			Total
	Comerica - Revolving Line of Credit, due 2014		$	3,638			—		$	3,638

	Total debt			3,638			—			3,638
	Less: debt - current			(3,638	)		—			(3,638	)

	Debt - non-current		$	—			—		$	—

	Debt at December 31, 2012, consisted of the following (in thousands):


			December 31, 2012
			Principal			Unamortized			Total
			Principal			Discount			Total
	Comerica - Growth Capital Loan A, due 2015		$	4,583		$	(49	)	$	4,534
	Comerica - Revolving Line of Credit, due 2014			3,190			—			3,190

	Total debt			7,773			(49	)		7,724
	Less: debt - current			(4,857	)		29			(4,828	)

	Debt - non-current		$	2,916		$	(20	)	$	2,896

	Principal and interest payments on debt at September 30, 2013, are expected to be as follows for each of the following five years (in thousands):


	Year ended December 31,
	2013 (remaining three months)		$	40
	2014 (1)			3,740
	2015			—
	2016			—
	2017			—

	-1	Included outstanding revolving line of credit balance based on the Company’s obligation to repay the outstanding revolving line of credit balance at the end of the revolving line of credit term.
	2011 Growth Capital Facility
	The Company entered into a loan and security agreement on September 30, 2011, as amended effective on December 13, 2011, and June 30, 2012, with Comerica Bank (“Comerica”) (collectively, the “Amended Credit Agreement”). The Amended Credit Agreement provides for an aggregate borrowing of up to $12.0 million, comprised of a growth capital loan of $5.0 million (“Growth Capital Loan”) and a formula based revolving line of credit (“RLOC”) of up to $7.0 million. The Company pledged all current and future assets, excluding its intellectual property and 35% of the Company’s investment in its subsidiary, Cerus Europe B.V., as security for borrowings under the Amended Credit Agreement.
	Growth Capital Loan
	Concurrent with the execution of the Amended Credit Agreement, in September 2011, the Company borrowed $5.0 million under the Growth Capital Loan, substantially all of which was used to repay the Company’s prior debt with Oxford Finance Corporation (“Oxford”), with the remainder used for general corporate purposes. The Growth Capital Loan, which was scheduled to mature on September 30, 2015, and bore a fixed interest rate of 6.37%, with interest–only payments due for the first twelve months, followed by equal principal and interest payments for the remaining 36 months. In April 2013, the Company repaid in full the Growth Capital Loan balance and all accrued interest as well as a scheduled final payment fee of $0.05 million, in an aggregate amount of $4.2 million. The Company has no further obligations under the Growth Capital Loan.
	In September 2011, the Company incurred a commitment fee of $40,000 and loan fees of $50,000, which were recorded as a discount to its Growth Capital Loan and were being amortized as a component of interest expense using the effective interest method over the term of the Growth Capital Loan (discount was based on an implied interest rate of 7.07%). The Company was also required to make a final payment fee of 1% of the amounts drawn under the Growth Capital Loan due on its prepayment of the Growth Capital Loan. The final payment fee was accreted to interest expense using the effective interest method over the life of the Growth Capital Loan upon draw. The remaining unaccreted balance of the final payment fee and unamortized discount was taken as an interest charge in April 2013 in connection with the repayment of that loan.

	Revolving Line of Credit
	The Amended Credit Agreement also provides for a RLOC of up to $7.0 million (the “RLOC Loan Amount”). The amount available under the RLOC is limited to the lesser of (i) 80% of eligible trade receivables or (ii) the RLOC Loan Amount. At September 30, 2013, and December 31, 2012, the Company had $3.6 million and $3.2 million, respectively, outstanding under the RLOC. The Company is required to repay the principal drawn from the RLOC at the end of the RLOC term on June 30, 2014, or earlier if a portion or all of the outstanding RLOC exceeds the amount available under the RLOC. The RLOC bears a floating rate based on the lender’s prime rate plus 1.50%, with interest–only payments due each month. At both September 30, 2013, and December 31, 2012, the floating rate of the RLOC was at 4.75%. In September 2011, the Company incurred a commitment fee of $20,000. Upon amendment of the loan and security agreement in June 2012, the Company incurred another annual commitment fee of $20,000 and received a credit for the unused portion of the initial fee. The Company incurs a $20,000 commitment fee at each annual anniversary beginning June 30, 2013.
	Compliance with Covenants
	The Company is required to maintain compliance with certain customary and routine financial covenants under the Amended Credit Agreement, including maintaining a minimum cash balance of $2.5 million at Comerica and achieving minimum revenue levels, which are measured monthly based on a six-month trailing basis and must be at least 75% of the pre-established future projected revenues for the trailing six-month period. Non-compliance with the covenants could result in the principal of the note becoming due and payable. As of September 30, 2013, the Company was in compliance with the financial covenants as set forth in the Amended Credit Agreement.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2013
Commitments and Contingencies	'
	Note 9. Commitments and Contingencies
	Operating Leases
	The Company leases its office facilities, located in Concord, California and Amersfoort, The Netherlands, and certain equipment under non-cancelable operating leases with initial terms in excess of one year that require the Company to pay operating costs, property taxes, insurance and maintenance. The operating leases expire at various dates through 2019, with certain of the leases providing for renewal options, provisions for adjusting future lease payments, which is based on the consumer price index and the right to terminate the lease early, which may occur as early as January 2015. In June 2013 the Company entered into a new lease for additional space in Concord. The lease has a two year initial term with four (4) two year options for the Company to renew. The lease commences on August 1, 2013 and obligates the Company to make rent payments of $51,456, $154,368 and $90,048 in 2013, 2014 and 2015, respectively. The Company’s leased facilities qualify as operating leases under ASC Topic 840, “Leases” and as such, are not included on its condensed consolidated balance sheets.
	Financed Leasehold Improvements
	In December 2010, the Company financed $1.1 million of leasehold improvements. The Company pays for the financed leasehold improvements as a component of rent and is required to reimburse its landlord over the remaining life of the respective leases. If the Company exercises its right to early terminate the Concord California lease, which may occur as early as January 2015, the Company would be required to repay for any remaining portion of the landlord financed leasehold improvements at such time. At September 30, 2013, the Company had an outstanding liability of $0.7 million related to these leasehold improvements, of which $0.1 million was reflected in “Accrued liabilities” and $0.6 million was reflected in “Other non-current liabilities” on the Company’s condensed consolidated balance sheets.
	Purchase Commitments
	The Company is party to agreements with certain providers for certain components of INTERCEPT Blood System which the Company purchases from third party manufacturers and supplies to Fresenius at no cost for use in manufacturing finished INTERCEPT disposable kits. Certain of these agreements require minimum purchase commitments from the Company.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2013
Stockholders' Equity	'
	Note 10. Stockholders’ Equity
	Series B Preferred Stock
	In March 1999, the Company issued 3,327 shares of the Company’s Series B preferred stock to Fresenius Kabi AG (“Fresenius”) (formerly, Baxter International Inc.). The Series B preferred stock had no voting rights, except with respect to the authorization of any class or series of stock having preference or priority over the Series B preferred stock as to voting, liquidation or conversion or with respect to the determination of fair value of non-publicly traded shares received by the holder of Series B preferred stock in the event of a liquidation, or except as required by Delaware law. At any time, the holder had the ability to convert each share of Series B preferred stock into 100 shares of the Company’s common stock. The Company had the right to redeem the Series B preferred stock prior to conversion for a payment of $9.5 million. In June 2012, Fresenius exercised its right to convert all 3,327 shares of the Company’s Series B preferred stock. As a result, the Company issued 332,700 shares of its common stock to Fresenius and retired the outstanding Series B preferred stock.
	Common Stock and Associated Warrant Liability
	In August 2009, the Company received net proceeds of approximately $12.1 million, after deducting placement agent’s fees and stock issuance costs of approximately $1.1 million, from a registered direct offering of 6.0 million units. Each unit sold consisted of one share of common stock and a warrant to purchase 4/10 of a share of common stock. Each unit was sold for $2.20, resulting in the issuance of 6.0 million shares of common stock and warrants to purchase 2.4 million shares of common stock, exercisable at an exercise price of $2.90 per share. The warrants issued in August 2009 (“2009 Warrants”) are exercisable for a period of five years from the issue date. The fair value on the date of issuance of the 2009 Warrants was determined to be $2.8 million using the binomial-lattice option valuation model and applying the following assumptions: (i) a risk-free rate of 2.48%, (ii) an expected term of 5.0 years, (iii) no dividend yield and (iv) a volatility of 77%.
	In November 2010, the Company received net proceeds of approximately $19.7 million, after deducting underwriting discounts and commissions and stock issuance costs of approximately $1.3 million, from an underwritten public offering of 7.4 million units. Each unit sold consisted of one share of common stock and a warrant to purchase 1/2 of a share of common stock. Each unit was sold for $2.85, resulting in the issuance of 7.4 million shares of common stock and warrants to purchase 3.7 million shares of common stock, exercisable at an exercise price of $3.20 per share. The warrants issued in November 2010 (“2010 Warrants”) became exercisable on May 15, 2011 and are exercisable for a period of five years from the issue date. The fair value on the date of issuance of the 2010 Warrants was determined to be $5.8 million using the binomial-lattice option valuation model and applying the following assumptions: (i) a risk-free rate of 1.23%, (ii) an expected term of 5.0 years, (iii) no dividend yield and (iv) a volatility of 85%.
	The fair value of the 2009 Warrants and 2010 Warrants was recorded on the condensed consolidated balance sheets as a liability pursuant to “Accounting for Derivative Instruments and Hedging Activities” and “Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity” Topics of ASC and will be adjusted to fair value at each financial reporting date thereafter until the earlier of exercise or modification to remove the provisions which require the warrants to be treated as a liability, at which time, these warrants would be reclassified into stockholders’ equity. The Company classified the 2009 Warrants and 2010 Warrants as a liability as these warrants contain certain provisions that, under certain circumstances, which may be out of the Company’s control, could require the Company to pay cash to settle the exercise of the warrants or may require the Company to redeem the warrants.
	The fair value of the warrants at September 30, 2013, and December 31, 2012, consisted of the following (in thousands):


		September 30,			December 31,
		2013			2012
	2009 Warrants	$	9,203		$	2,009
	2010 Warrants		13,503			3,894

	Total warrant liability	$	22,706		$	5,903

	The fair value of the Company’s warrants was based on using the binomial-lattice option valuation model and using the following assumptions at September 30, 2013, and December 31, 2012:


		September 30,			December 31,
		2013			2012
	2009 Warrants:
	Expected term (in years)		0.9			1.65
	Estimated volatility		43	%		45	%
	Risk-free interest rate		0.1	%		0.25	%
	Expected dividend yield		0	%		0	%
	2010 Warrants:
	Expected term (in years)		2.11			2.86
	Estimated volatility		41	%		51	%
	Risk-free interest rate		0.33	%		0.36	%
	Expected dividend yield		0	%		0	%
	For the three months ended September 30, 2013, and 2012, the Company recorded a non-cash charge of $12.4 million and non-cash gain of $0.9 million, respectively, on its condensed consolidated statements of operations within non-operating income (expense), net, due to the changes in fair value of the warrants. For the nine months ended September 30, 2013, and 2012, the Company recorded a non-cash charge of $16.8million and a non-cash gain of $0.1 million, respectively, on its condensed consolidated statements of operations within non-operating income (expense), net, due to the changes in fair value of the warrants. Significant changes to the Company’s market price for its common stock will impact the fair value the warrants. As a result, any significant increases in the Company’s stock price will likely create an increase to the fair value of warrant liability. At September 30, 2013, the 2010 Warrants to purchase 5,084 shares of common stock had been exercised.
	Sales Agreements
	The Company entered into an At-The-Market Issuance Sales Agreement in June 2011, as amended in January 2012 and August 2012 (collectively, the “MLV Agreement”), with MLV & Co. LLC, formerly McNicoll, Lewis & Vlak LLC (“MLV”) that provides for the issuance and sale of shares of the Company’s common stock over the term of the MLV Agreement having an aggregate offering price of up to $20.0 million through MLV. Under the MLV Agreement, MLV acts as the Company’s sales agent and receives compensation based on an aggregate of 3% of the gross proceeds on the sale price per share of its common stock. The issuance and sale of these shares by the Company pursuant to the MLV Agreement are deemed an “at-the-market” offering and are registered under the Securities Act. Over the term of the MLV Agreement, approximately 6.6 million shares of the Company’s common stock were sold under the MLV Agreement for aggregate net proceeds of $19.2 million. At September 30, 2013, the Company had less than $0.1 million of common stock available to be sold under the MLV Agreement. During the nine months ended September 30, 2013, the Company had no sales of its common stock under the MLV Agreement.
	The Company also entered into a Controlled Equity OfferingSM Sales Agreement (the “Cantor Agreement”) in August 2012, with Cantor Fitzgerald & Co. (“Cantor”) that provides for the issuance and sale of shares of its common stock over the term of the Cantor Agreement having an aggregate offering price of up to $30.0 million through Cantor. Under the Cantor Agreement, Cantor also acts as the Company’s sales agent and receives compensation based on an aggregate of 2% of the gross proceeds on the sale price per share of its common stock. The issuance and sale of these shares by the Company pursuant to the Cantor Agreement are deemed an “at-the-market” offering and are registered under the Securities Act. During the year ended December 31, 2012, approximately 1.4 million shares of the Company’s common stock were sold under the Cantor Agreement for aggregate net proceeds of $4.3 million. During the nine months ended September 30, 2013, approximately 3.8 million shares of the Company’s common stock were sold under the Cantor Agreement for aggregate net proceeds of $13.0 million, all of which were sold in the first quarter of 2013. At September 30, 2013, the Company had approximately $12.5 million of common stock available to be sold under the Cantor Agreement.
	Public Offering of Common Stock
	The Company completed a public offering of common stock on March 19, 2013. As a result of this offering, the Company issued approximately 8.3 million shares of its common stock at $4.20 per share. The Company provided the underwriters an overallotment of an additional approximately 1.3 million shares of its common stock, which was fully subscribed. Combined gross proceeds for the offering were approximately $40.3 million. Net proceeds to the Company were approximately $38.0 million after underwriters’ discount of approximately $1.8 million and offering costs of approximately $0.5 million.
	Stockholder Rights Plan
	In October 2009, the Company’s Board of Directors adopted an amendment to its 1999 stockholder rights plan, commonly referred to as a “poison pill,” to reduce the exercise price, extend the expiration date and revise certain definitions under the plan. The stockholder rights plan is intended to deter hostile or coercive attempts to acquire the Company. The stockholder rights plan enables stockholders to acquire shares of the Company’s common stock, or the common stock of an acquirer, at a substantial discount to the public market price should any person or group acquire more than 15% of the Company’s common stock without the approval of the Board of Directors under certain circumstances. The Company has designated 250,000 shares of Series C Junior Participating preferred stock for issuance in connection with the stockholder rights plan.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2013
Stock-Based Compensation	'
	Note 11. Stock-Based Compensation
	The Company maintains an equity compensation plan to provide long-term incentives for employees, contractors, and members of its Board of Directors. The Company currently grants equity awards from one plan, the 2008 Equity Incentive Plan (the “2008 Plan”). The 2008 Plan allows for the issuance of non-statutory and incentive stock options, restricted stock, restricted stock units, stock appreciation rights, other stock-related awards, and performance awards which may be settled in cash, stock, or other property. The Company continues to have equity awards outstanding under its previous stock plans: 1998 Non-Officer Stock Option Plan and 1999 Equity Incentive Plan (collectively, the “Prior Plans”) and 1996 Equity Incentive Plan (the “1996 Plan”). Equity awards issued under the Prior Plans and the 1996 Plan continue to adhere to the terms of those respective stock plans and no further options may be granted under those previous plans. However, at June 2, 2008, any shares that remained available for future grants under the Prior Plans became available for issuance under the 2008 Plan. On June 6, 2012, and June 12, 2013, the stockholders approved an amendments to the 2008 Plan (“Amended 2008 Plan”) which increased the aggregate number of shares of common stock authorized for issuance by 3,000,000 and 6,000,000 shares, respectively, such that the Amended 2008 Plan has reserved for issuance an amount not to exceed 19,540,940 shares effective June 12, 2013. At September 30, 2013, the Company had an aggregate of approximately 12.7 million shares of its common stock reserved for issuance under the Amended 2008 Plan, the Prior Plans and the 1996 Plan, of which approximately 10.6 million shares were subject to outstanding options and other stock-based awards, and approximately 8.1 million shares were available for future issuance under the Amended 2008 Plan.

	The Company also maintains an Employee Stock Purchase Plan (the “Purchase Plan”) which is intended to qualify as an employee stock purchase plan within the meaning of Section 423(b) of the Internal Revenue Code. Under the Purchase Plan, the Company’s Board of Directors may authorize participation by eligible employees, including officers, in periodic offerings. On June 6, 2012, the stockholders approved an amendment to the Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance by 500,000 shares, such that the Purchase Plan has reserved for issuance an amount not to exceed 1,320,500 shares. At September 30, 2013, the Company had approximately 0.5 million shares available for future issuance under the Purchase Plan.
	The Company has granted restricted stock units to its senior management in accordance with the Amended 2008 Plan. Subject to each grantee’s continued employment, the restricted stock units vest in three annual installments from the date of grant and are generally issuable at the end of the three-year vesting term.
	Activity under the Company’s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):


		Number of			Weighted
		Options			Average
		Outstanding			Exercise
					Price per
					Share
	Balance at December 31, 2012		8,504		$	3.4
	Granted		2,503			3.69
	Forfeited		(111	)		3.19
	Expired		(189	)		6.71
	Exercised		(177	)		2.5

	Balance at September 30, 2013		10,530		$	3.43

	The Company currently uses the Black-Scholes option pricing model to determine the grant-date fair value of stock options and employee stock purchase plan shares. The Black-Scholes option pricing model is affected by the Company’s stock price, as well as assumptions regarding a number of complex and subjective variables, which include the expected term of the grants, actual and projected employee stock option exercise behaviors, including forfeitures, the Company’s expected stock price volatility, the risk-free interest rate and expected dividends. The Company recognizes the grant-date fair value of the stock award as stock-based compensation expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures.
	Stock-based compensation recognized on the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2013, and 2012, was as follows (in thousands):


		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013		2012
	Stock-based compensation expense by caption:
	Research and development	$	132		$	146	$	341	$	423
	Selling, general and administrative		729			549		2,074		1,488

	Total stock-based compensation expense	$	861		$	695	$	2,415	$	1,911

	The Company did not record any stock-based compensation associated with performance-based stock options during the three and nine months ended September 30, 2013, and 2012, as the performance criteria was not probable of being achieved during these periods. Performance-based stock options of 50,000 remained outstanding at September 30, 2013.

License_Agreements

License Agreements	9 Months Ended
License Agreements	Sep. 30, 2013
License Agreements	'
	Note 12. License Agreements
	The Company has certain agreements with Fresenius under which the Company pays royalties on future INTERCEPT Blood System product sales which utilize certain intellectual property rights held by Fresenius at royalty rates that vary by product: 10% of product sales for the platelet system, 3% of product sales for the plasma system, 5% of product sales for the red blood cell system, and 6.5% on sales of illuminators. During each the three months ended September 30, 2013, and 2012, the Company made separate royalty payments to Fresenius of $0.8 million and $0.7 million, respectively, and payments of $2.3 million and $2.1 million during the nine months ended September 30, 2013 and 2012, respectively. At both September 30, 2013, and December 31, 2012, the Company accrued royalties of $0.7 million and $0.8 million, respectively.
	In December 2008, the Company extended its agreement with Fresenius to manufacture finished INTERCEPT disposable kits for the platelet and plasma systems through December 31, 2013. Under the amended manufacturing and supply agreement, the Company pays Fresenius a set price per kit, which is established annually, plus a fixed surcharge per kit. In addition, volume driven manufacturing overhead is to be paid or refunded if actual manufacturing volumes are lower or higher than the estimated production volumes. The Company made payments to Fresenius of $4.2 million and $1.4 million relating to the manufacturing of the Company products during the three months ended September 30, 2013, and 2012, respectively, and $11.8 million and $8.9 million, during the nine months ended September 30, 2013 and 2012, respectively. At September 30, 2013, and December 31, 2012, the Company owed Fresenius $4.3 million and $6.2 million, respectively, for INTERCEPT disposable kits manufactured. In connection with the warranty claims incurred by the Company and remediation of those claims during the year ended December 31, 2012 (see Note 1 in the Notes to Condensed Consolidated Financial Statements under “Guarantee and Indemnification Arrangements” for more detail), the Company filed a warranty claim against Fresenius. Fresenius accepted the warranty claim and has supplied the Company with replacement product or credit notes. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheets as of December 31, 2012 representing the full amount of the warranty claim against Fresenius. As of September 30, 2013 the Company no longer has a warranty claim against Fresenius and all unsalable inventory has been returned to Fresenius.

Segment_Customer_and_Geographi

Segment, Customer and Geographic Information	9 Months Ended
Segment, Customer and Geographic Information	Sep. 30, 2013
Segment, Customer and Geographic Information	'
	Note 13. Segment, Customer and Geographic Information
	The Company continues to operate in only one segment, blood safety. The Company’s chief executive officer is the chief operating decision maker who evaluates performance based on the net revenues and operating loss of the blood safety segment. The Company considers the sale of all of its INTERCEPT Blood System products to be similar in nature and function, and any revenue earned from services is minimal.
	The Company’s operations outside of the United States include a wholly-owned subsidiary headquartered in Europe. The Company’s operations in the United States are responsible for the research and development and global commercialization of the INTERCEPT Blood System, as discussed in further detail below, while operations in Europe are responsible for the commercialization efforts of the platelet and plasma systems in Europe, The Commonwealth of Independent States and the Middle East. Product revenues are attributed to each region based on the location of the customer, and in the case of non-product revenues, on the location of the collaboration partner.
	The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, all of which operate in a country outside of the United States, during the three and nine months ended September 30, 2013, and 2012 (in percentages):


			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Etablissement Francais du Sang			20	%		22	%		18	%		23	%
	Movaco, S.A.			19	%		19	%		16	%		19	%
	Bravo Pacific Limited			11	%			*			*			*
	Advanced Technology Comp. KSC			10	%			*			*			*
	AUM+ LTD				*		13	%			*			*

	*	Represents an amount less than 10% of product revenue.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Principles of Consolidation and Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include those of Cerus Corporation and its subsidiary, Cerus Europe B.V. (collectively referred to hereinafter as “Cerus” or the “Company”) after elimination of all intercompany accounts and transactions. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of only normal recurring entries, considered necessary for a fair presentation have been made. Operating results for the three and nine months ended September 30, 2013, are not necessarily indicative of the results that may be expected for the year ending December 31, 2013, or for any future periods.

These condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2012, which were included in the Company’s 2012 Annual Report on Form 10-K, filed with the SEC on March 12, 2013. The accompanying balance sheet as of December 31, 2012, has been derived from the Company’s audited financial statements as of that date.

Use of Estimates

The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, which are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.

Revenue

The Company recognizes revenue in accordance with ASC Topic 605-25, “Revenue Recognition—Arrangements with Multiple Deliverables,” as applicable. Revenue is recognized when (i) persuasive evidence of an agreement with the funding party exists; (ii) services have been rendered or product has been delivered; (iii) pricing is fixed or determinable; and (iv) collection is reasonably assured. The Company’s main sources of revenues for the three and nine months ended September 30, 2013, and 2012, were product revenue from sales of the INTERCEPT Blood System for platelets and plasma (“platelet and plasma systems”) and United States government grants and awards.

Revenue related to product sales is generally recognized when the Company fulfills its obligations for each element of an agreement. For all sales of the Company’s INTERCEPT Blood System products, the Company uses a binding purchase order and signed sales contract as evidence of a written agreement. The Company sells its platelet and plasma systems directly to blood banks, hospitals, universities, government agencies, as well as to distributors in certain regions. Generally, the Company’s contracts with its customers do not provide for open return rights, except within a reasonable time after receipt of goods in the case of defective or non-conforming product. Deliverables and the units of accounting vary according to the provisions of each purchase order or sales contract. For revenue arrangements with multiple elements, the Company determines whether the delivered elements meet the criteria as separate units of accounting. Such criteria require that the deliverable have stand-alone value to the customer and that if a general right of return exists relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Once the Company determines if the deliverable meets the criteria for a separate unit of accounting, the Company must determine how the consideration should be allocated between the deliverables and how the separate units of accounting should be recognized as revenue. Consideration received is allocated to elements that are identified as discrete units of accounting based on the best estimated selling price. The Company has determined that vendor specific objective evidence is not discernible due to the Company’s limited history of selling its products and variability in its pricing across the regions into which it sells its products. Since the Company’s products are novel and unique and are not sold by others, third-party evidence of selling price is unavailable.

At both September 30, 2013, and December 31, 2012, the Company had $0.1 million of short-term deferred revenue on its condensed consolidated balance sheets related to future performance obligations. Freight costs charged to customers are recorded as a component of revenue under ASC Topic 605, “Accounting for Shipping and Handling Fees and Costs.” Value-added-taxes (“VAT”) that the Company invoices to its customers and remits to governments are recorded on a net basis, which excludes such VAT from product revenue.

Revenue related to the cost reimbursement provisions under development contracts or United States government grants is recognized as the costs on the projects are incurred. The Company has received certain United States government grants and contracts that support research in defined research projects. These grants generally have provided for reimbursement of approved costs incurred as defined in the various grants.

Research and Development Expenses

In accordance with ASC Topic 730, “Accounting for Research and Development Expenses,” research and development expenses are charged to expense when incurred, including cost incurred under each grant that has been awarded to the Company by the United States government or development contracts. Research and development expenses include salaries and related expenses for scientific personnel, payments to consultants, supplies and chemicals used in in-house laboratories, costs of research and development facilities, depreciation of equipment and external contract research expenses, including clinical trials, preclinical safety studies, other laboratory studies, process development and product manufacturing for research use.

The Company’s use of estimates in recording accrued liabilities for research and development activities (see “Use of Estimates” above) affects the amounts of research and development expenses recorded and revenue recorded from development funding and government grants and collaborative agreements. Actual results may differ from those estimates under different assumptions or conditions.

Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be classified as cash equivalents. These investments primarily consist of money market instruments, and are classified as available-for-sale.

Short-Term Investments

Investments with original maturities of greater than three months but less than one year from the date of purchase as well as available-for-sale investments with original maturities of greater than one year from the date of purchase, which included corporate bonds and United States government agency securities, are classified as short-term investments. In accordance with ASC Topic 320, “Accounting for Certain Investments in Debt and Equity Securities,” the Company has classified all debt securities as available-for-sale at the time of purchase and reevaluates such designation as of each balance sheet date. Available-for-sale securities are carried at estimated fair value. Unrealized gains and losses derived by changes in the estimated fair value of available-for-sale securities are recorded in “Accumulated other comprehensive income” on the Company’s condensed consolidated balance sheets and in “Net unrealized losses on available-for-sale securities, net of taxes” on the Company’s condensed consolidated statements of comprehensive loss. Realized gains and losses from the sale or maturity of available-for-sale investments are recorded in “Other income, net” on the Company’s condensed consolidated statements of operations. The cost of securities sold is based on the specific identification method. The Company reports the amortization of any premium and accretion of any discount resulting from the purchase of debt securities as a component of interest expense.

The Company also reviews all of its marketable securities on a regular basis to evaluate whether any security has experienced an other-than-temporary decline in fair value. Other-than-temporary declines in market value are recorded in “Other income (expense), net” on the Company’s condensed consolidated statements of operations.

Restricted Cash

The Company holds a certificate of deposit with a domestic bank for any potential decommissioning resulting from the Company’s possession of radioactive material. The certificate of deposit is held to satisfy the financial surety requirements of the California Department of Health Services and is recorded in “Restricted cash” on the Company’s condensed consolidated balance sheets.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.

Pursuant to the Company’s investment policy, substantially all of the Company’s cash, cash equivalents and short-term investments are maintained at two major financial institutions of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company’s investments carry high credit quality ratings, which is in accordance with its investment policy. At September 30, 2013, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company’s cash equivalents.

Concentrations of credit risk with respect to trade receivables exist. However, in connection with the Company’s revolving line of credit, as discussed in Note 8 in the Notes to Condensed Consolidated Financial Statements, the Company purchased a credit insurance policy that mitigates some of its credit risk, as the policy will pay either the Company or its lender on eligible claims filed on its outstanding receivables. On a regular basis, including at the time of sale, the Company performs credit evaluations of its customers. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company reserves against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations. The Company has not historically experienced significant bad debt and accordingly has not maintained an allowance for doubtful accounts.

The Company had three customers that accounted for more than 10% of the Company’s outstanding trade receivables at both September 30, 2013, and December 31, 2012. These customers cumulatively represented approximately 55% and 59% of the Company’s outstanding trade receivables, at September 30, 2013 and December 31, 2012, respectively. To date, the Company has not experienced collection difficulties from these customers.

Inventories

At September 30, 2013, and December 31, 2012, inventory consisted of work-in-process and finished goods only. Finished goods include INTERCEPT disposable kits, UVA illumination devices (“illuminators”), and certain replacement parts for the illuminators. Platelet and plasma systems’ disposable kits generally have a two-year life from the date of manufacture. Illuminators and replacement parts do not have regulated expiration dates. Work-in-process includes certain components that are manufactured over a protracted length of time, which can exceed one year, before being incorporated and assembled by Fresenius Kabi AG (“Fresenius”) into the finished INTERCEPT disposable kits. The Company maintains an inventory balance based on its current sales projections, and at each reporting period, the Company evaluates whether its work-in-process inventory would be consumed for production of finished units in order to sell to existing and prospective customers within the next twelve-month period. It is not customary for the Company’s production cycle for inventory to exceed twelve months. Instead, the Company uses its best judgment to factor in lead times for the production of its finished units to meet the Company’s current demands. If actual results differ from those estimates, work-in-process inventory could potentially accumulate for periods exceeding one year. At September 30, 2013 and December 31, 2012, the Company classified its work-in-process inventory as a current asset on its condensed consolidated balance sheets based on its evaluation that the work-in-process inventory would be consumed for production and subsequently sold within each respective subsequent twelve-month period.

Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, or market value. The Company uses significant judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. Generally, the Company writes-down specifically identified unusable, obsolete, slow-moving, or known unsalable inventory that has no alternative use in the period that it is first recognized by using a number of factors including product expiration dates, open and unfulfilled orders, and sales forecasts. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded in “Cost of product revenue” on the Company’s condensed consolidated statements of operations.

Property and Equipment, net

Property and equipment is comprised of furniture, equipment, information technology hardware and software and is recorded at cost. At the time the property and equipment is ready for its intended use, it is depreciated on a straight-line basis over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or the estimated useful lives of the improvements.

Goodwill and Intangible Assets, net

Additions to goodwill and intangible assets, net are derived at the time of a business acquisition, in which the Company assigns the total consideration transferred to the acquired assets based on each asset’s fair value and any residual amount becomes goodwill, an indefinite life intangible asset. Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, are subject to ratably amortized over the estimated useful life of ten years. The amortization of the Company’s intangible assets, net, is recorded in “Amortization of intangible assets” on the Company’s condensed consolidated statements of operations.

Goodwill is not amortized but instead is subject to an impairment test performed on an annual basis, or more frequently if events or changes in circumstances indicate that goodwill may be impaired. The Company evaluates goodwill on an annual basis on August 31 of each fiscal year. The test for goodwill impairment is a two-step process. The first step compares the fair value of each reporting unit with its respective carrying amount, including goodwill. The Company has determined that it operates in one reporting unit and estimates the fair value of its one reporting unit using the enterprise approach under which it considers the quoted market capitalization of the Company as reported on the Nasdaq Global Market. The Company considers quoted market prices that are available in active markets to be the best evidence of fair value. The Company also considers other factors, which include future forecasted results, the economic environment and overall market conditions. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired and, therefore, the second step of the impairment test is unnecessary. The second step, which is used to measure the amount of impairment loss, compares the implied fair value of each reporting unit’s goodwill with the respective carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess.

See Note 5 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s impairment analysis and the valuation of goodwill and intangible assets, net.

Long-lived Assets

The Company evaluates its long-lived assets for impairment by continually monitoring events and changes in circumstances that could indicate carrying amounts of its long-lived assets may not be recoverable. When such events or changes in circumstances occur, the Company assesses recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the expected undiscounted future cash flows are less than the carrying amount of these assets, the Company then measures the amount of the impairment loss based on the excess of the carrying amount over the fair value of the assets. The Company did not recognize impairment charges related to its long-lived assets during the three and nine months ended September 30, 2013, and 2012.

Foreign Currency Remeasurement

The functional currency of the Company’s foreign subsidiary is the United States dollar. Monetary assets and liabilities denominated in foreign currencies are remeasured in United States dollars using the exchange rates at the balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are remeasured in United States dollars using historical exchange rates. Revenues and expenses are remeasured using average exchange rates prevailing during the period. Remeasurements are recorded in the Company’s condensed consolidated statements of operations. The Company recorded foreign currency gains (losses) of $0.4 million and $0.2 million during the three months ended September 30, 2013, and 2012, respectively, and $0.2 million and $(0.05) during the nine months ended September 30, 2013, and 2012, respectively.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, “Compensation—Stock Compensation.” Stock-based compensation expense is measured at the grant-date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is the vesting period, and is adjusted for estimated forfeitures. To the extent that stock options contain performance criteria for vesting, stock-based compensation is recognized once the performance criteria are probable of being achieved.

For stock-based awards issued to non-employees, the Company follows ASC Topic 505-50, “Equity Based Payment to Non-Employees” and considers the measurement date at which the fair value of the stock-based award is measured to be the earlier of (i) the date at which a commitment for performance by the grantee to earn the equity instrument is reached or (ii) the date at which the grantee performance is complete. The Company recognizes stock-based compensation expense for the fair value of the vested portion of the non-employee stock-based awards in its condensed consolidated statements of operations.

See Note 11 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s stock-based compensation assumptions and expenses.

Warrant Liability

In August 2009, and November 2010, the Company issued warrants to purchase an aggregate of 2.4 million and 3.7 million shares of common stock, respectively. The material terms of the warrants were identical under each issuance except for the exercise price, date issued and expiration date. The Company classified the warrants as a liability on its condensed consolidated balance sheets as the warrants contain certain material terms which require the Company (or its successor) to purchase the warrants for cash in an amount equal to the value of the unexercised portion of the warrants (as determined in accordance with the Black-Scholes option pricing model) in connection with certain change of control transactions. In addition, the Company may also be required to pay cash to a warrant holder under certain circumstances if the Company is unable to timely deliver the shares acquired upon warrant exercise to such holder.

The fair value of these outstanding warrants is calculated using the binomial-lattice option-pricing model and is adjusted accordingly at each reporting period. The binomial-lattice option-pricing model requires that the Company uses significant assumptions and judgment to determine appropriate inputs to the model. Some of the assumptions that the Company relies on include the probability of a change of control occurring, the volatility of the Company’s stock over the life of the warrant and assumptions and inputs used to value the warrants under the Black-Scholes model should a change of control occur.

Changes resulting from the revaluation of warrants to fair value are recorded in “Revaluation of warrant liability” on the condensed consolidated statements of operations. Upon the exercise or modification to remove the provisions which require the warrants to be treated as a liability, the fair value of the warrants will be reclassified from a liability to stockholders’ equity on the Company’s condensed consolidated balance sheets and no further adjustment to the fair value would be made in subsequent periods.

See Note 10 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s valuation of warrant liability.

Income Taxes

The Company accounts for income taxes using an asset and liability approach in accordance with ASC Topic 740 “Accounting for Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. ASC Topic 740 requires derecognition of tax positions that do not have a greater than 50% likelihood of being recognized upon review by a taxing authority having full knowledge of all relevant information. Use of a valuation allowance as described in ASC Topic 740 is not an appropriate substitute for the derecognition of a tax position. The Company did not have any recorded liabilities for unrecognized tax benefits at September 30, 2013 or December 31, 2012. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. To date, the Company has not recognized any interest and penalties in its condensed consolidated statements of operations, nor has its accrued for or made payments for interest and penalties. The Company continues to carry a full valuation allowance on all of its deferred tax assets. Although the Company believes it more likely than not that a taxing authority would agree with its current tax positions, there can be no assurance that the tax positions the Company has taken will be substantiated by a taxing authority if reviewed. The Company’s tax years 1998 through 2012 remain subject to examination by the taxing jurisdictions.

Net Loss Per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted loss per common share gives effect to all potentially dilutive common shares outstanding for the period. The potentially dilutive securities include stock options, employee stock purchase plan rights, warrants and restricted stock units, which are calculated using the treasury stock method, and convertible preferred stock, which is calculated using the if-converted method. Diluted loss per common share also gives effect to potential adjustments to the numerator for changes resulting from the revaluation of warrants to fair value for the period, even if the Company is in a net loss position if the effect would result in more dilution.

Diluted loss per common share used the same weighted average number of common shares outstanding for the three months ended September 30, 2013 and the nine months ended September 30, 2013, and 2012, as calculated for the basic loss per common share as the inclusion of any potential dilutive securities would be anti-dilutive. In addition, certain potential dilutive securities were excluded from the dilution calculation for the three months ended September 30, 2012, as their inclusion would have been anti-dilutive.

The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2013, and 2012 (in thousands, except per share amounts):

Three Months Ended

Nine Months Ended

September 30,

2013

2012

2013

2012

Numerator:

Net loss used for basic calculation

(20,501

)

(3,460

)

(37,477

)

(14,201

)

Effect of revaluation of warrant liability

—

(873

)

—

Adjusted net loss used for diluted calculation

(20,501

)

(4,333

)

(37,477

)

(14,201

)

Denominator:

Basic weighted average number of common shares outstanding

69,791

54,875

66,464

54,130

Effect of dilutive potential common shares resulting from warrants

—

502

—

Diluted weighted average number of common shares outstanding

69,791

55,377

66,464

54,130

Net loss per common share:

Basic

(0.29

)

(0.06

)

(0.56

)

(0.26

)

Diluted

(0.29

)

(0.08

)

(0.56

)

(0.26

)

The table below presents common shares underlying stock options, convertible preferred stock, employee stock purchase plan rights, warrants and restricted stock units that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the three and nine months ended September 30, 2013, and 2012 (shares in thousands):

Three Months Ended

Nine Months Ended

September 30,

2013

2012

2013

2012

Anti-dilutive common shares

16,651

8,704

16,301

14,813

Guarantee and Indemnification Arrangements

The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company after December 31, 2002. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company’s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company’s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.

The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. During the year ended December 31, 2012, the Company provided for warranty obligations related to replacement costs for certain of its products that the Company identified were defective or had the potential of being defective. In connection with the warranty obligations provided for in relation to certain of its products during the year ended December 31, 2012, the Company filed a warranty claim against Fresenius, which Fresenius accepted. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheet as of December 31, 2012 representing the full amount of the warranty claim against Fresenius as Fresenius was obliged to supply the Company with replacement products or credit notes for those defective or potentially defective products. The Company also wrote-down the value of certain unsalable inventory of $1.7 million related to these products as an offsetting warranty claim against Fresenius as of December 31, 2012. As of September 30, 2013, the Company no longer has a warranty claim against Fresenius and all unsalable inventory related to this incident has been returned to Fresenius. During the three months ended March 31, 2013, the Company identified a separate production defect related to unsold inventory. The Company’s third party manufacturer has taken responsibility for the cost of replacing such damaged goods, therefore, the Company has borne no costs associated with these defects. Prior to these incidents, there have been very few warranty costs incurred. As a result, the Company did not accrue for any potential future warranty costs at September 30, 2013. In addition, the Company believes that the defective products and those that had the potential of being defective identified during the three months ended March 31, 2013 and during the year ended December 31, 2012 are isolated.

Fair Value of Financial Instruments

The Company determines the fair value relating to its financial assets and liabilities. The carrying amounts of accounts receivables, accounts payable, and other accrued liabilities approximate their fair value due to the relative short-term maturities. Based on the borrowing rates currently available to the Company for loans with similar terms, the Company believes the fair value of its debt approximates their carrying amounts. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis, including its available-for-sale securities and warrant liability. The Company classifies financial instruments within Level 1 if quote prices are available in active markets, which include its money market funds as the money market funds are actively traded in markets and their market price can be readily determined. The Company classifies instruments in Level 2 if the instruments are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. These instruments include the Company’s available-for-sale securities related to United States government agencies. The available-for-sale securities are held by a custodian who obtains investment prices from a third party pricing provider that uses standard inputs to models which vary by asset class. The Company classifies instruments in Level 3 if one or more significant inputs or significant value drivers are unobservable, which include its warrant liability. The Company assesses any transfers among fair value measurement levels at the end of each reporting period.

See Note 2 and 10 in the Notes to Condensed Consolidated Financial Statements for further information regarding the Company’s valuation on financial instruments.

New Accounting Pronouncements

In February 2013, Accounting Standards Codification Topic 220, Comprehensive Income, was amended to require additional information about amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning January 1, 2013, and will provide the additional information when such reclassifications occur. The amendment did not have a material effect on our consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2013
Computation of Basic and Diluted Net Loss per Common Share	'
	The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2013, and 2012 (in thousands, except per share amounts):


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Numerator:
	Net loss used for basic calculation	$	(20,501	)	$	(3,460	)	$	(37,477	)	$	(14,201	)
	Effect of revaluation of warrant liability		—			(873	)		—			—

	Adjusted net loss used for diluted calculation	$	(20,501	)	$	(4,333	)	$	(37,477	)	$	(14,201	)

	Denominator:
	Basic weighted average number of common shares outstanding		69,791			54,875			66,464			54,130
	Effect of dilutive potential common shares resulting from warrants		—			502			—			—

	Diluted weighted average number of common shares outstanding		69,791			55,377			66,464			54,130

	Net loss per common share:
	Basic	$	(0.29	)	$	(0.06	)	$	(0.56	)	$	(0.26	)
	Diluted	$	(0.29	)	$	(0.08	)	$	(0.56	)	$	(0.26	)
Anti-Dilutive Effect of Common Shares	'
	The table below presents common shares underlying stock options, convertible preferred stock, employee stock purchase plan rights, warrants and restricted stock units that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect for the three and nine months ended September 30, 2013, and 2012 (shares in thousands):


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Anti-dilutive common shares		16,651			8,704			16,301			14,813

Fair_Value_on_Financial_Instru1

Fair Value on Financial Instruments (Tables)	9 Months Ended
Fair Value on Financial Instruments (Tables)	Sep. 30, 2013
Fair Value of Financial Assets and Liabilities	'
	The fair values of certain of the Company’s financial assets and liabilities were determined using the following inputs at September 30, 2013 (in thousands):


			Total		Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active		Observable		Inputs
					Markets for		Inputs		(Level 3)
					Identical		(Level 2)
					Assets
					(Level 1)
	Money market funds (1)		$	7,862	$	7,862	$	—	$	—
	Corporate debt securities (2)			24,948		—		24,948		—
	United States government agency securities (2)			4,023		—		4,023		—

	Total financial assets		$	36,833	$	7,862	$	28,971	$	—


	Warrant liability		$	22,706	$	—	$	—	$	22,706

	Total financial liabilities		$	22,706	$	—	$	—	$	22,706


	-1	Included in cash and cash equivalents on the Company’s condensed consolidated balance sheets.
	-2	Included in short-term investments on the Company’s condensed consolidated balance sheets.
	The fair values of certain of the Company’s financial assets and liabilities were determined using the following inputs at December 31, 2012 (in thousands):


			Total		Quoted		Significant		Significant
					Prices in		Other		Unobservable
					Active		Observable		Inputs
					Markets for		Inputs		(Level 3)
					Identical		(Level 2)
					Assets
					(Level 1)
	Money market funds (1)		$	10,268	$	10,268	$	—	$	—

	Total financial assets		$	10,268	$	10,268	$	—	$	—


	Warrant liability		$	5,903	$	—	$	—	$	5,903

	Total financial liabilities		$	5,903	$	—	$	—	$	5,903


	-1	Included in cash and cash equivalents on the Company’s condensed consolidated balance sheets.
Reconciliation of Fair Value Measurement on Liabilities Using Significant Unobservable Inputs	'
	A reconciliation of the beginning and ending balances for warrant liability using significant unobservable inputs (Level 3) from December 31, 2012, to September 30, 2013, was as follows (in thousands):


	Balance at December 31, 2012		$	5,903
	Increase in fair value of warrants			16,803
	Settlement of warrants exercised			—

	Balance at September 30, 2013		$	22,706

Availableforsale_Securities_Ta

Available-for-sale Securities (Tables)	9 Months Ended
Available-for-sale Securities (Tables)	Sep. 30, 2013
Summary of Available for Sale Securities	'
	The following is a summary of available-for-sale securities at September 30, 2013 (in thousands):


		September 30, 2013
		Amortized Cost		Gross			Fair Value
		Amortized Cost		Unrealized Loss			Fair Value
	Money market funds	$	7,862				$	7,862
	United States government agency securities		4,027		(4	)		4,023
	Corporate debt securities		24,977		(29	)		24,948

	Total available-for-sale securities	$	36,866	$	(33	)	$	36,833

Available for Sale Securities by Original Contractual Maturity	'
	Available-for-sale securities at September 30, 2013 and December 31, 2012, consisted of the following by original contractual maturity (in thousands):


		September 30, 2013					December 31, 2012
		Amortized Cost		Fair Value			Amortized Cost		Fair Value
	Due in one year or less	$	24,509	$	24,492		$	10,268	$	10,268
	Due greater than one year and less than five years		12,357		12,341			—		—

	Total available-for-sale securities	$	36,866	$	36,833		$	10,268	$	10,268

Inventories_Tables

Inventories (Tables)	9 Months Ended
Inventories (Tables)	Sep. 30, 2013
Inventories	'
	Inventories at September 30, 2013 and December 31, 2012, consisted of the following (in thousands):


		September 30,		December 31,
		2013		2012
	Work-in-process	$	4,810	$	3,551
	Finished goods		7,876		6,629

	Total inventories	$	12,686	$	10,180

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, net (Tables)	9 Months Ended
Goodwill and Intangible Assets, net (Tables)	Sep. 30, 2013
Summary of Intangible Assets	'
	The following is a summary of intangible assets, net at September 30, 2013 (in thousands):


		September 30, 2013
		Gross		Accumulated			Net
		Carrying		Amortization			Carrying
		Amount					Amount
	Acquisition-related intangible assets:
	Reacquired license - INTERCEPT Asia	$	2,017	$	(622	)	$	1,395

	Total intangible assets	$	2,017	$	(622	)	$	1,395

	The following is a summary of intangible assets, net at December 31, 2012 (in thousands):


		December 31, 2012
		Gross		Accumulated			Net
		Carrying		Amortization			Carrying
		Amount					Amount
	Acquisition-related intangible assets:
	Reacquired license - INTERCEPT Asia	$	2,017	$	(471	)	$	1,546

	Total intangible assets	$	2,017	$	(471	)	$	1,546

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
Accrued Liabilities (Tables)	Sep. 30, 2013
Accrued Liabilities	'
	Accrued liabilities at September 30, 2013 and December 31, 2012, consisted of the following (in thousands):


		September 30,		December 31,
		2013		2012
	Accrued compensation and related costs	$	2,588	$	2,692
	Accrued inventory costs		5,115		2,352
	Accrued contract and other accrued expenses		4,357		2,575

	Total accrued liabilities	$	12,060	$	7,619

Debt_Tables

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2013
Debt	'
	Debt at September 30, 2013, consisted of the following (in thousands):


			September 30, 2013
			Principal			Unamortized			Total
			Principal			Discount			Total
	Comerica - Revolving Line of Credit, due 2014		$	3,638			—		$	3,638

	Total debt			3,638			—			3,638
	Less: debt - current			(3,638	)		—			(3,638	)

	Debt - non-current		$	—			—		$	—

	Debt at December 31, 2012, consisted of the following (in thousands):


			December 31, 2012
			Principal			Unamortized			Total
			Principal			Discount			Total
	Comerica - Growth Capital Loan A, due 2015		$	4,583		$	(49	)	$	4,534
	Comerica - Revolving Line of Credit, due 2014			3,190			—			3,190

	Total debt			7,773			(49	)		7,724
	Less: debt - current			(4,857	)		29			(4,828	)

	Debt - non-current		$	2,916		$	(20	)	$	2,896

Expected Principal and Interest Payments on Debt	'
	Principal and interest payments on debt at September 30, 2013, are expected to be as follows for each of the following five years (in thousands):


	Year ended December 31,
	2013 (remaining three months)		$	40
	2014 (1)			3,740
	2015			—
	2016			—
	2017			—

	-1	Included outstanding revolving line of credit balance based on the Company’s obligation to repay the outstanding revolving line of credit balance at the end of the revolving line of credit term.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
Stockholders' Equity (Tables)	Sep. 30, 2013
Fair Value of Warrants	'
	The fair value of the warrants at September 30, 2013, and December 31, 2012, consisted of the following (in thousands):


		September 30,			December 31,
		2013			2012
	2009 Warrants	$	9,203		$	2,009
	2010 Warrants		13,503			3,894

	Total warrant liability	$	22,706		$	5,903

Fair Value Assumptions of Warrants	'
	The fair value of the Company’s warrants was based on using the binomial-lattice option valuation model and using the following assumptions at September 30, 2013, and December 31, 2012:


		September 30,			December 31,
		2013			2012
	2009 Warrants:
	Expected term (in years)		0.9			1.65
	Estimated volatility		43	%		45	%
	Risk-free interest rate		0.1	%		0.25	%
	Expected dividend yield		0	%		0	%
	2010 Warrants:
	Expected term (in years)		2.11			2.86
	Estimated volatility		41	%		51	%
	Risk-free interest rate		0.33	%		0.36	%
	Expected dividend yield		0	%		0	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2013
Activity Under Equity Incentive Plans Related to Stock Options	'
	Activity under the Company’s equity incentive plans related to stock options is set forth below (in thousands except per share amounts):


		Number of			Weighted
		Options			Average
		Outstanding			Exercise
					Price per
					Share
	Balance at December 31, 2012		8,504		$	3.4
	Granted		2,503			3.69
	Forfeited		(111	)		3.19
	Expired		(189	)		6.71
	Exercised		(177	)		2.5

	Balance at September 30, 2013		10,530		$	3.43

Recognition of Stock-Based Compensation Expense	'
	Stock-based compensation recognized on the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2013, and 2012, was as follows (in thousands):


		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013		2012
	Stock-based compensation expense by caption:
	Research and development	$	132		$	146	$	341	$	423
	Selling, general and administrative		729			549		2,074		1,488

	Total stock-based compensation expense	$	861		$	695	$	2,415	$	1,911

Segment_Customer_and_Geographi1

Segment, Customer and Geographic Information (Tables)	9 Months Ended
Segment, Customer and Geographic Information (Tables)	Sep. 30, 2013
Customers that Accounted for More Than Ten Percent of Total Product Revenue	'
	The Company had the following significant customers that accounted for more than 10% of the Company’s total product revenue, all of which operate in a country outside of the United States, during the three and nine months ended September 30, 2013, and 2012 (in percentages):


			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Etablissement Francais du Sang			20	%		22	%		18	%		23	%
	Movaco, S.A.			19	%		19	%		16	%		19	%
	Bravo Pacific Limited			11	%			*			*			*
	Advanced Technology Comp. KSC			10	%			*			*			*
	AUM+ LTD				*		13	%			*			*

	*	Represents an amount less than 10% of product revenue.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Share data in Millions, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Aug. 31, 2009

Nov. 30, 2010

Sep. 30, 2013

Dec. 31, 2012

Customer

Product Warranty

2009 Unit Offering

2010 Unit Offering

Maximum

Minimum

Warrant

Summary Of Significant Accounting Policies [Line Items]

Deferred revenue

$111,000

$77,000

Number of major customers representing outstanding trade receivables

Cumulative outstanding trade receivables percentage by major customers

55.00%

59.00%

10.00%

Life of inventory

'2 years

Protracted length of inventory

'1 year

Estimated useful life of property and equipment

'5 years

'3 years

Estimated useful life of intangible assets

'10 years

Impairment charges on long-lived assets

Foreign currency gains (losses)

409,000

187,000

198,000

-53,000

Warrants to purchase an aggregate shares of common stock

2.4

3.7

Company's tax years subject to examination by the taxing jurisdictions

'2012

'1998

Unrecognized Tax Benefits

Warranty claim

394,000

2,038,000

1,800,000

Inventory write down

$1,700,000

Period of warranty

'1 year

Reconciliation_of_Numerator_an

Reconciliation of Numerator and Denominator Used in Computation of Basic and Diluted Net Income Loss per Common Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net loss used for basic calculation	($20,501)	($3,460)	($37,477)	($14,201)
Effect of revaluation of warrant liability	'	-873	'	'
Adjusted net loss used for diluted calculation	($20,501)	($4,333)	($37,477)	($14,201)
Denominator	'	'	'	'
Basic weighted average number of common shares outstanding	69,791	54,875	66,464	54,130
Effect of dilutive potential common shares resulting from warrants	'	502	'	'
Diluted weighted average number of common shares outstanding	69,791	55,377	66,464	54,130
Net loss per common share:	'	'	'	'
Basic	($0.29)	($0.06)	($0.56)	($0.26)
Diluted	($0.29)	($0.08)	($0.56)	($0.26)

Common_Shares_Underlying_Stock

Common Shares Underlying Stock Options Convertible Preferred Stock Employee Stock Purchase Plan Rights Warrants and Restricted Stock Units Excluded from Calculation of Weighted Average Number of Common Shares Outstanding used for Calculation of Diluted Net Income Loss Per Common Share (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive common shares	16,651	8,704	16,301	14,813

Fair_Value_on_Financial_Assets

Fair Value on Financial Assets and Liabilities (Detail) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Fair value of financial assets and liabilities	'		'
Total financial assets	$36,833		$10,268
Total financial liabilities	22,706		5,903
Money market funds	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	7,862	[1]	10,268	[1]
Corporate debt securities	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	24,948	[2]	'
United States government agency securities	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	4,023	[2]	'
Warrant Liability	'		'
Fair value of financial assets and liabilities	'		'
Total financial liabilities	22,706		5,903
Quoted Prices in Active Markets for Identical Assets (Level 1)	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	7,862		10,268
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	7,862	[1]	10,268	[1]
Significant Other Observable Inputs (Level 2)	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	28,971		'
Significant Other Observable Inputs (Level 2) \| Corporate debt securities	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	24,948	[2]	'
Significant Other Observable Inputs (Level 2) \| United States government agency securities	'		'
Fair value of financial assets and liabilities	'		'
Total financial assets	4,023	[2]	'
Significant Unobservable Inputs (Level 3)	'		'
Fair value of financial assets and liabilities	'		'
Total financial liabilities	22,706		5,903
Significant Unobservable Inputs (Level 3) \| Warrant Liability	'		'
Fair value of financial assets and liabilities	'		'
Total financial liabilities	$22,706		$5,903

[1]	Included in cash and cash equivalents on the Company's condensed consolidated balance sheets.
[2]	Included in short-term investments on the Company's condensed consolidated balance sheets.

Reconciliation_of_Beginning_an

Reconciliation of Beginning and Ending Balances for Warrant Liability Using Significant Unobservable Inputs (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning balance	$5,903
Increase in fair value of warrants	16,803
Settlement of warrants exercised	'
Ending balance	$22,706

Summary_of_Available_for_Sale_

Summary of Available for Sale Securities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$36,866	'
Gross Unrealized Loss	-33	'
Fair Value	36,833	10,268
Money market funds	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	7,862	'
Fair Value	7,862	'
United States government agency securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	4,027	'
Gross Unrealized Loss	-4	'
Fair Value	4,023	'
Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	24,977	'
Gross Unrealized Loss	-29	'
Fair Value	$24,948	'

Available_for_Sale_Securities_

Available for Sale Securities by Original Contractual Maturity (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Due in one year or less, amortized cost	$24,509	$10,268
Due greater than one year and less than five years, amortized cost	12,357	'
Total available-for-sale securities, amortized cost	36,866	10,268
Due in one year or less, fair value	24,492	10,268
Due greater than one year and less than five years, fair value	12,341	'
Total available-for-sale securities, fair value	$36,833	$10,268

AvailableforSale_Securities_Ad

Available-for-Sale Securities - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Gross realized gains from the sale or maturity of available-for-sale investments	$0	$0	$0	$0
Other-than-temporary impairments from the sale or maturity of available-for-sale investments	$0	$0	$0	$0

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Work-in-process	$4,810	$3,551
Finished goods	7,876	6,629
Total inventories	$12,686	$10,180

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Disposal or recognition of additional goodwill	$0	'	$0	'	'
Impairment charges on goodwill	0	'	0	'	'
Goodwill balance	1,316,000	'	1,316,000	'	1,316,000
Amortization expenses of intangible assets	50,000	50,000	151,000	151,000	'
Impairment charges recognized related to the acquired intangible assets	0	0	0	0	'
Annual amortization expense of the intangible assets, 2013 (remaining six months)	50,000	'	50,000	'	'
Annual amortization expense of the intangible assets, 2014	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2015	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2016	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2017	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2018	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2019	200,000	'	200,000	'	'
Annual amortization expense of the intangible assets, 2020	$100,000	'	$100,000	'	'

Summary_of_Intangible_Assets_N

Summary of Intangible Assets Net (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$2,017	$2,017
Accumulated Amortization	-622	-471
Net Carrying Amount	1,395	1,546
Reacquired license - INTERCEPT Asia	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	2,017	2,017
Accumulated Amortization	-622	-471
Net Carrying Amount	$1,395	$1,546

LongTerm_Investments_Additiona

Long-Term Investments - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Investment [Line Items]	'	'
Eligibility to receive a royalty fee	1.00%	'
Royalty income, nonoperating	$0	'
Carrying value of investment	$0	$0
Maximum	'	'
Investment [Line Items]	'	'
Ownership percentage under Cost Method for Investments	3.00%	'

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Schedule of Accrued Liabilities [Line Items]	'	'
Accrued compensation and related costs	$2,588	$2,692
Accrued inventory costs	5,115	2,352
Accrued contract and other accrued expenses	4,357	2,575
Total accrued liabilities	$12,060	$7,619

Debt_Detail

Debt (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Total debt, Principal	$3,638	$7,773
Total debt, Unamortized amount	'	-49
Total debt	3,638	7,724
Less: debt - current, Principal	-3,638	-4,857
Less: debt - current, Unamortized Discount	'	29
Less: debt - current	-3,638	-4,828
Debt - non-current, Principal	'	2,916
Debt - non-current, Unamortized Discount	'	-20
Debt - non-current	'	2,896
Comerica - Growth Capital Loan A, due 2015	'	'
Debt Instrument [Line Items]	'	'
Total debt, Principal	'	4,583
Total debt, Unamortized amount	'	-49
Total debt	'	4,534
Comerica - Revolving Line of Credit, due 2014	'	'
Debt Instrument [Line Items]	'	'
Total debt, Principal	3,638	3,190
Total debt	$3,638	$3,190

Principal_and_Interest_Payment

Principal and Interest Payments on Debt (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified	Sep. 30, 2013
Debt Instrument [Line Items]	'
2013 (remaining three months)	$40
2014	3,740	[1]
2015	'
2016	'
2017	'

[1]	Included outstanding revolving line of credit balance based on the Company's obligation to repay the outstanding revolving line of credit balance at the end of the revolving line of credit term.

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	Jun. 30, 2012	Sep. 30, 2013	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2011	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Apr. 30, 2013	Sep. 30, 2011
	Securities Pledged as Collateral	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Compliance With Covenants	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Revolving Credit Facility	Capital Loan	Capital Loan
					Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility	Comerica - Growth Capital Facility
Line of Credit Facility [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Amended Credit Agreement	'	'	$12,000,000	'	'	$7,000,000	'	'	'	'	$5,000,000
Growth capital loan from amended Credit Agreement	'	'	'	'	'	'	'	'	'	'	5,000,000
Percentage of investments made in subsidiary	35.00%	'	'	'	'	'	'	'	'	'	'
Principal and interest payments	'	'	'	'	'	'	'	'	'	'	'Growth Capital Loan, which matures on September 30, 2015, bears a fixed interest rate of 6.37%, with interest-only payments due for the first twelve months, followed by equal principal and interest payments for the remaining 36 months.
Maturity period	'	'	'	'	'	'	'	30-Jun-14	'	'	30-Sep-15
Fixed interest rate	'	'	'	'	'	'	'	'	'	'	6.37%
Interest Only payments Period	'	'12 months	'	'	'	'	'	'	'	'	'
Principal and interest payments	'	'36 months	'	'	'	'	'	'	'	'	'
Final payment fee for early repayment of credit facility	'	'	'	'	'	'	'	'	'	50,000	'
Repayment of credit facility	'	'	'	'	'	'	'	'	'	4,200,000	'
Commitment fee	'	'	'	'	20,000	20,000	'	'	'	'	40,000
Loan fees	'	'	'	'	'	'	'	'	'	'	50,000
Effective interest rate	'	'	'	'	'	'	'	'	'	'	7.07%
Final payment fee percentage	'	'	'	'	'	'	'	'	'	'	1.00%
Amount under RLOC available to the Company	'	'	'	'	'	'	80.00%	'	'	'	'
Outstanding amounts	'	'	'	'	'	'	3,600,000	'	3,200,000	'	'
Lender's prime rate plus 1.50%	'	'	'	'	'	'	'	'Lender's prime rate plus 1.50%	'	'	'
Margin rate	'	'	'	'	'	'	1.50%	'	'	'	'
Floating rate of interest	'	'	'	'	'	'	4.75%	'	4.75%	'	'
Frequency of commitment fee	'	'	'	'	'	'	'	'Annually on June 30	'	'	'
Commitment fee at each annual anniversary beginning June 30, 2013	'	'	'	'	'	'	'	20,000	'	'	'
Minimum cash balance	'	'	'	$2,500,000	'	'	'	'	'	'	'
Minimum revenues levels percentage	'	'	'	75.00%	'	'	'	'	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2010
Commitments and Contingencies Disclosure [Line Items]	'	'
Minimum term of non-cancellable operating leases	'1 year	'
Expiration of non-cancellable operating leases maximum year	'2019	'
Financing for leasehold improvement	'	$1,100,000
Outstanding liability related to leasehold improvements	700,000	'
Leasehold Improvements reflected in Accrued liabilities	100,000	'
Leasehold Improvements reflected in Other non-current liabilities	600,000	'
Additional Concord Lease	'	'
Commitments and Contingencies Disclosure [Line Items]	'	'
Early termination of non-cancellable operating leases minimum period	'2015-01	'
Initial term of operating lease	'2 years	'
Number of renewal options	4	'
Renewal period of operating lease	'2 years	'
Lease commencement date	1-Aug-13	'
Future rent payment, 2013	51,456	'
Future rent payment, 2014	154,368	'
Future rent payment, 2015	$90,048	'

Stockholders_Equity_Additional

Stockholders Equity - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Mar. 19, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Sep. 30, 2013

Mar. 31, 1999

Jun. 30, 2012

Aug. 31, 2009

Nov. 30, 2010

Sep. 30, 2013

IPO

Stockholder Rights Plan

Sales Agreement

Series B Preferred Stock

Common Stock

Warrant

Overallotment Option

Mlv

Cantor

2009 Unit Offering

2010 Unit Offering

Maximum

Stockholders Equity Note [Line Items]

Preferred stock issued

3,327

Preferred stock conversion basis to common shares

100

Redeemable preferred stock, amount

$9,500,000

Conversion of preferred stock to Common stock

3,327

Common stock issued to Fresenius

332,700

Conversion of preferred stock to common stock date

30-Jun-12

Warrants to purchase an aggregate shares of common stock

2,400,000

3,700,000

Net proceeds from underwritten public offering

12,100,000

19,700,000

Payment for underwriting discounts and commissions and stock issuance cost

500,000

1,100,000

1,300,000

Number of units sold in underwritten public offering

6,000,000

7,400,000

Number of common stock in each unit

Number of common stock shares purchasable with each warrant

0.4

0.5

Units issues, price per unit

$2.20

Common stock, number of shares issued

6,600,000

3,800,000

1,400,000

6,000,000

7,400,000

Warrant exercise price

2.9

3.2

Exercisable period

'5 years

Warrant liability

22,706,000

5,903,000

2,800,000

5,800,000

Risk-free rate

2.48%

1.23%

Expected term

'5 years

Dividend yield

0.00%

Volatility

77.00%

85.00%

Units issued, price per unit

$2.85

Warrants exercisable date

15-May-11

Gain (Loss) from Revaluation of warrant liability

-12,416,000

873,000

-16,803,000

86,000

Warrants exercised

5,084

Maximum common stock offering price

20,000,000

30,000,000

Percentage of proceeds payable as compensation to underwriter

3.00%

2.00%

Proceeds from common stock sold

50,981,000

10,823,000

38,000,000

19,200,000

13,000,000

4,300,000

Common stock available for sale

100,000

12,500,000

Common stock, number of shares issued

8,300,000

1,300,000

Common stock, price per share

$4.20

Gross proceeds from public offering

40,300,000

Underwriter's discount

$1,800,000

Minimum percentage of common stock acquired by stockholders

15.00%

Designated preferred stock for future issuance

250,000

Fair_Value_of_Warrants_Detail

Fair Value of Warrants (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Warrant liability	$22,706	$5,903
2009 Warrants	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant liability	9,203	2,009
2010 Warrants	'	'
Class of Warrant or Right [Line Items]	'	'
Warrant liability	$13,503	$3,894

Fair_Value_of_Warrants_Using_V

Fair Value of Warrants Using Valuation Model (Detail)	9 Months Ended	12 Months Ended
Fair Value of Warrants Using Valuation Model (Detail)	Sep. 30, 2013	Dec. 31, 2012
2009 Warrants	'	'
Class of Warrant or Right [Line Items]	'	'
Expected term (in years)	'10 months 24 days	'1 year 7 months 24 days
Estimated volatility	43.00%	45.00%
Risk-free interest rate	0.10%	0.25%
Expected dividend yield	0.00%	0.00%
2010 Warrants	'	'
Class of Warrant or Right [Line Items]	'	'
Expected term (in years)	'2 years 1 month 10 days	'2 years 10 months 10 days
Estimated volatility	41.00%	51.00%
Risk-free interest rate	0.33%	0.36%
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 06, 2012	Sep. 30, 2013	Jun. 12, 2013	Jun. 06, 2012
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Employee Stock Purchase Plan	Employee Stock Purchase Plan	2008 Equity Incentive Plan	2008 Equity Incentive Plan	2008 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Increase in shares of common stock authorized for issuance	'	'	'	'	500,000	'	6,000,000	3,000,000
Maximum number of shares of common stock authorized for issuance	'	'	'	'	1,320,500	'	'	19,540,940
Aggregate number of shares of common stock reserved for future issuance	12,700,000	12,700,000	'	'	'	'	'	'
Outstanding options and other stock based awards	10,600,000	10,600,000	'	'	'	'	'	'
Number of shares available for future issuance	'	'	'	500,000	'	8,100,000	'	'
Restricted stock units vesting Description	'	'The restricted stock units vest in three annual installments from the date of grant and are generally issuable at the end of the three-year vesting term	'	'	'	'	'	'
Performance-based stock options awards	$0	'	$0	'	'	'	'	'
Performance-based stock options, outstanding	50,000	50,000	'	'	'	'	'	'

Activity_Under_Equity_Incentiv

Activity Under Equity Incentive Plans Related to Stock Options (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Activity under the Company's equity incentive plans related to stock options	'
Balance at December 31, 2012, Number of Options Outstanding	8,504
Granted, Number of Options Outstanding	2,503
Forfeited, Number of Options Outstanding	-111
Expired, Number of Options Outstanding	-189
Exercised, Number of Options Outstanding	-177
Balance at September 30, 2013, Number of Options Outstanding	10,530
Weighted Average Exercise Price per Share	'
Balance at December 31, 2012, Weighted Average Exercise Price per Share	$3.40
Granted, Weighted Average Exercise Price per Share	$3.69
Forfeited, Weighted Average Exercise Price per Share	$3.19
Expired, Weighted Average Exercise Price per Share	$6.71
Exercised, Weighted Average Exercise Price per Share	$2.50
Balance at September 30, 2013, Weighted Average Exercise Price per Share	$3.43

StockBased_Compensation_Recogn

Stock-Based Compensation Recognized on Condensed Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$861	$695	$2,415	$1,911
Research and Development Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	132	146	341	423
Selling, General and Administrative Expenses	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$729	$549	$2,074	$1,488

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Licenses Agreements [Line Items]	'	'	'	'	'
Royalty payments on products	$800,000	$700,000	$2,300,000	$2,100,000	'
Payments made relating to the manufacturing of the products	4,200,000	1,400,000	11,800,000	8,900,000	'
Current asset, warrant claim	394,000	'	394,000	'	2,038,000
Product Warranty	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Current asset, warrant claim	0	'	0	'	1,800,000
Royalty	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Manufacturing costs owed	700,000	'	700,000	'	800,000
Royalty \| Platelet system	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Royalty rate applied towards sale of products	'	'	10.00%	'	'
Royalty \| Plasma system	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Royalty rate applied towards sale of products	'	'	3.00%	'	'
Royalty \| Red blood cell system	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Royalty rate applied towards sale of products	'	'	5.00%	'	'
Royalty \| Illuminators	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Royalty rate applied towards sale of products	'	'	6.50%	'	'
Manufacturing Costs	'	'	'	'	'
Licenses Agreements [Line Items]	'	'	'	'	'
Manufacturing costs owed	$4,300,000	'	$4,300,000	'	$6,200,000

Segment_Customer_and_Geographi2

Segment, Customer and Geographic Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting Information [Line Items]	'
Number of operating segments	1

Significant_Customers_that_Acc

Significant Customers that Accounted for More than Ten Percentage of Total Product Revenue (Detail)	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Etablissement Francais du Sang	'		'		'		'
Revenue, Major Customer [Line Items]	'		'		'		'
Percentage of revenue derived from significant customer from Company's total product revenue	20.00%		22.00%		18.00%		23.00%
Movaco, S.A.	'		'		'		'
Revenue, Major Customer [Line Items]	'		'		'		'
Percentage of revenue derived from significant customer from Company's total product revenue	19.00%		19.00%		16.00%		19.00%
Bravo Pacific Limited	'		'		'		'
Revenue, Major Customer [Line Items]	'		'		'		'
Percentage of revenue derived from significant customer from Company's total product revenue	11.00%		'	[1]	'	[1]	'	[1]
Advanced Technology Comp. KSC	'		'		'		'
Revenue, Major Customer [Line Items]	'		'		'		'
Percentage of revenue derived from significant customer from Company's total product revenue	10.00%		'	[1]	'	[1]	'	[1]
AUM+ LTD	'		'		'		'
Revenue, Major Customer [Line Items]	'		'		'		'
Percentage of revenue derived from significant customer from Company's total product revenue	'	[1]	13.00%		'	[1]	'	[1]

[1]	Represents an amount less than 10% of product revenue.